Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets
Authors: Michael L. Maitland, Mark J. Ratain
Journal: Annals of Internal Medicine (2006)

Editorials7 November 2006Terminal Ballistics of Kinase Inhibitors: There Are No Magic BulletsMichael L. Maitland, MD, PhD and Mark J. Ratain, MDMichael L. Maitland, MD, PhDFrom University of Chicago, Chicago, Illinois. and Mark J. Ratain, MDFrom University of Chicago, Chicago, Illinois.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-145-9-200611070-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Terminal ballistics is the study of the motion and consequent effects of projectiles, especially bullets, as they interact with their intended targets. How ammunition behaves once it enters and (sometimes) exits the body is crucial information for emergency physicians and trauma surgeons for optimal management of gunshot wounds (1). Since the "founder of chemotherapy," Paul Ehrlich, described a drug that would eliminate disease precisely and efficiently as a "magic bullet," oncologists have been prone to militaristic metaphors (2). For optimal care of patients with cancer, it has become increasingly important for oncologists and their internal medicine colleagues to study the ...References1. Volgas DA, Stannard JP, Alonso JE. Ballistics: a primer for the surgeon. Injury. 2005;36:373-9. [PMID: 15710153] CrossrefMedlineGoogle Scholar2. Hall SS. A Commotion in the Blood: Life, Death, and the Immune System. New York: Henry Holt; 1997. Google Scholar3. Verweij J, Judson I, van Oosterom A. STI571: a magic bullet? Eur J Cancer. 2001;37:1816-9. [PMID: 11576833] CrossrefMedlineGoogle Scholar4. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-16. [PMID: 16862153] CrossrefMedlineGoogle Scholar5. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-13. [PMID: 16687713] CrossrefMedlineGoogle Scholar6. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab [Letter]. N Engl J Med. 2006;354:980-2; discussion 980-2. [PMID: 16510760] Google Scholar7. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab [Letter]. N Engl J Med. 2006;354:980-2; discussion 980-2. [PMID: 16514715] Google Scholar8. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-4. LinkGoogle Scholar9. Shaheen PE, Tamaskar IR, Salas RN, Rini BI, Garcia J, Wood L, et al. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib [Abstract]. J Clin Oncol. 2006;24 18 Suppl 4605. CrossrefGoogle Scholar10. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290:H560-76. [PMID: 16172168] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Chicago, Chicago, Illinois.Disclosures: Consultancies: M.J. Ratain (Novartis and Genentech); Honoraria: M.L. Maitland (Bayer), M.J. Ratain (Onyx); Expert testimony: M.J. Ratain (Pfizer); Grants received: M.J. Ratain (Bayer); Grants pending: M.L. Maitland (Bayer); Patents pending: M.L. Maitland and M.J. Ratain (sorafenib [Bayer and Onyx] for the treatment of pulmonary hypertension).Corresponding Author: Mark J. Ratain, MD, University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637; e-mail, [email protected]bsd.uchicago.edu.Current Author Addresses: Drs. Maitland and Ratain: University of Chicago, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors Jayesh Desai , Leila Yassa , Ellen Marqusee , Suzanne George , Mary C. Frates , Ming Hui Chen , Jeffrey A. Morgan , Samuel S. Dychter , P. Reed Larsen , George D. Demetri , and Erik K. Alexander Metrics Cited ByIdentifying Novel Drug Targets by iDTPnd: A Case Study of Kinase InhibitorsCardio-oncology Related to Heart FailureInhibidores de tirosina cinasa y disfunción tiroideaErlotinibLapatinibInterstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centresHypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative StressNew Trial Designs and Potential Therapies for Pulmonary Artery HypertensionMechanism of hypertension and proteinuria during angiogenesis inhibitionMolecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer TherapeuticsVEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCACorrelation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resectionBevacizumab-Induced HypertensionBioengineering approaches to study multidrug resistance in tumor cellsVascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care ProvidersKinase inhibition-related adverse events predicted from in vitro kinome and clinical trial dataA Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial HypertensionDRUGS USED IN CANCER CHEMOTHERAPYPatients with CancerTyrosine kinase inhibitors and the thyroidAmbulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of TreatmentCardiovascular toxicity of molecularly targeted agentsHypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapyCardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal TumorsAdvances in Cancer TherapeuticsArterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumabTyrosine Kinase Inhibitors: Can Promising New Therapy Associated With Cardiac Toxicity Strengthen the Concept of Teamwork?Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapyMechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer TherapeuticsTyrosine Kinase Inhibitors and the Thyroid as Both an Unintended and an Intended TargetCardiotoxicity of Antitumor Drugs †Challenges in Combinational Oncology StudiesBasic Science for the Clinician 48: Tyrosine Kinases in DiseaseCancerCytostatic and cytotoxic drugsEndocrine sequelae of cancer and cancer treatmentsHypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker?Anthracycline Cardiotoxicity 7 November 2006Volume 145, Issue 9Page: 702-703KeywordsAdverse reactionsDrugsGastrointestinal stromal tumorsHypothyroidismKinase inhibitorsRenal cell carcinomaThyroidToxicity ePublished: 7 November 2006 Issue Published: 7 November 2006 CopyrightCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...